Aldagen Inc. has announced the beginning of Phase III clinical trials in which the first pediatric patient has been treated with a proprietary adult stem cell product specifically developed as a therapeutic modality for inherited metabolic diseases.
The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of multiple sclerosis with the use of a therapeutic product developed from mesenchymal stromal cells.
As the first clinical trials ever to be conducted in the U.S. with embryonic stem cells are about to commence, FDA regulators convene a special meeting to debate the inherent risks and dangers.
The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of ischemic stroke with the use of a therapeutic product developed from mesenchymal stromal cells.
Scientists, doctors, patients and lawmakers work together to draft a state law that would expedite the storage and therapeutic administration of umbilical cord blood stem cells.
The discovery of mesenchymal stem cells in the eye has vast implications.
